Business NewsPR NewsWire • TaiGen Biotechnology Obtains the Worldwide Rights for Nemonoxacin

TaiGen Biotechnology Obtains the Worldwide Rights for Nemonoxacin

TaiGen Biotechnology Obtains the Worldwide Rights for Nemonoxacin

TAIPEI, Taiwan, Dec. 9, 2011 /PRNewswire-Asia/ -- TaiGen Biotechnology ("TaiGen") announced today that Warner Chilcott will transfer the worldwide rights for nemonoxacin, a novel non-fluorinated quinolone antibiotic under development for treatment of antibiotic-resistant infection to...

View More : http://www.prnewswire.com/news-releases/taigen-biotechnology-obtains-the-worldwide-rights-for-nemonoxacin-135306093.html
Releted News by prnewswire
TaiGen Biotechnology Obtains the Worldwide Rights for Nemonoxacin
NHS National Innovation Centre Estimates Sequana Medical's ALFApump® System Could Save the NHS £50 Million in ascites Care Annually
Washington, D.C. Budget Hotels Score Best Ratings, Survey Reveals